Brisbane, United States
Mammoth Biosciences, founded in 2017 by CRISPR pioneer and Nobel laureate Jennifer Doudna along with Trevor Martin, Janice Chen, and Lucas Harrington, is at the forefront of biotechnology innovation. With the slogan, "Improving lives by reading and writing the code of life," the company focuses on leveraging its proprietary ultracompact CRISPR systems to develop transformative therapies and applications such as decentralized precision diagnostics.
Headquartered in the United States, Mammoth Biosciences is advancing in vivo gene editing, using its technologies for applications beyond double-stranded breaks, including base editing, gene writing, and epigenetic editing. Supported by a robust intellectual property portfolio, the company's significant progress attracts partnerships with leading pharmaceutical entities such as Regeneron Pharmaceuticals.
Their recent funding round, a $100.00M late-stage VC investment led by Regeneron Pharmaceuticals, demonstrates strong confidence in their mission to transform patient lives and unlock CRISPR's full potential.
Synthego
